Lexapro: The First Victim of Part D?
This article was originally published in RPM Report
A slowdown in sales of Forest's flagship antidepressant Lexapro left analysts confused: generic versions of Celexa seem to be weighing down the new product, but why did the impact suddenly arrive in the third quarter? A recently policy pronouncement from CMS may be a clue.
You may also be interested in...
Defining Line Extensions: Medicaid Rebate Change Gives CMS Power to take a Bite Out of Lifecycle Management
A new provision in the health care reform law means that new formulations of oral brand name drugs will be subject to additional rebates. But who is affected depends in part on how CMS defines a line extension.
Biopharma in 2008: What a Difference an Economic Crisis Makes
Even before the financial meltdown, 2008 was a remodeling year for the biopharmaceutical world. Many pharma companies, more reliant on the product candidates and technologies of the biotech world than ever, were pinned down by excess infrastructure and lagging productivity. But when the world's cash dried up, so, too, did biotech's leverage over those downtrodden in-licensers and acquirers. We highlight some top trends from a difficult year that may shape industry in 2009 and beyond.
Paying for Protection: Medicare Rebates May Make Protected Classes Less Safe for Sponsors
Democrats failed in their first attempt to impose price controls in Medicare Part D. But, led by California Rep. Waxman, they may have found a new approach that seems less threatening than price negotiations-rebates for products used by dual eligible patients. And the drugs most likely to be affected are in Part D's six protected classes.